
Palvella Therapeutics ( ($PVLA) ) just unveiled an announcement. On November 19, 2026, Palvella Therapeutics announced QTORIN™ docetaxel as the third product candidate from its QTORIN™ platform, developed for extramammary
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| PVLA | Palvella Therapeutics | 145.77 | 54.74 | 60.13% |
| Name | Price | % Change | |
|---|---|---|---|
| $145.77 | +60.13% |

Palvella Therapeutics ( ($PVLA) ) just unveiled an announcement. On November 19, 2026, Palvella Therapeutics announced QTORIN™ docetaxel as the third product candidate from its QTORIN™ platform, developed for extramammary

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by

As previously reported, Leerink initiated coverage of Palvella Therapeutics (PVLA) with an Outperform rating and $228 price target The firm believes the investment case centers on 3 debates, namely whether

Leerink initiated coverage of Palvella Therapeutics (PVLA) with an Outperform rating and $228 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try

Palvella Therapeutics, Inc. (($PVLA)) has held its Q3 earnings call. Read on for the main highlights of the call. Palvella Therapeutics delivered a strongly positive earnings call, driven by FDA

Welcome to this week’s installment of “The Short Interest Report” – The Fly’s weekly recap of short interest trends among some of the most widely followed high-short-float stocks. Using the

Canaccord raised the firm’s price target on Palvella Therapeutics (PVLA) to $243 from $232 and keeps a Buy rating on the shares. The fdirm updated its model following Q3 results

Raymond James raised the firm’s price target on Palvella Therapeutics (PVLA) to $230 from $226 and keeps a Strong Buy rating on the shares. Palvella continues to advance QTORIN toward

Craig-Hallum raised the firm’s price target on Palvella Therapeutics (PVLA) to $230 from $205 and keeps a Buy rating on the shares. The firm cites a high likelihood of Qtorin

Analyst Jeet Mukherjee of BTIG maintained a Buy rating on Palvella Therapeutics, retaining the price target of $215.00. Jeet Mukherjee’s rating is based on the favorable setup for Palvella Therapeutics’
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | Nov 9, 2026 | ||||
| buy | Reiterated | Nov 6, 2026 | ||||
| buy | Reiterated | Nov 6, 2026 | ||||
| buy | Reiterated | Nov 6, 2026 | ||||
| buy | Reiterated | Nov 6, 2026 | ||||
| buy | Reiterated | Nov 6, 2026 | ||||
| buy | Reiterated | Nov 5, 2026 | ||||
| buy | Reiterated | Oct 29, 2026 | ||||
| buy | Reiterated | Oct 28, 2026 | ||||
| buy | Reiterated | Oct 21, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Apr 5, 2027TBA | $2.14B | $-1.96 | $0.00 | 0.54 | -26.65 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.